Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Second-hand tobacco smoke exposure results in NAFLD

A team of scientists at the University of California, Riverside has found that even second-hand tobacco smoke exposure can result in nonalcoholic fatty liver disease (NAFLD), a common disease and rising cause of chronic liver injury in which fat accumulates in the liver of people who drink little or no alcohol.

11 Sep 2009

Endothelin research update to be presented at APS' 11th International Conference

Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

10 Sep 2009

Therapeutic principles of monoclonal antibodies

Professor Joachim R. Kalden, Member of the Department for Molecular Immunology, Nikolaus-Fiebiger-Zentrum, University Medical School Erlangen-Nuremberg, presents therapeutic principles based on monoclonal antibodies.

10 Sep 2009

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

When bees sting, they pump into their victims a peptide toxin called melittin that destroys cell membranes. Now, by encapsulating this extremely potent molecule within a nanoparticle, researchers at the Washington University School of Medicine in St. Louis have created a potential new type of anticancer therapy with the potential to target a wide range of tumors. This work was reported in the Journal of Clinical Investigation.

7 Sep 2009

94-year-old crusader seeks ban on trans fats in the American diet

Fred Kummerow, a 94-year-old University of Illinois veterinary biosciences professor emeritus who still conducts research on the health effects of trans fats in the diet, filed the petition with the FDA last month. The petition is now posted on the FDA Web site, and public comments are invited. (See below for information on viewing the petition and making a comment.)

4 Sep 2009

LifeVantage granted third patent for Protandim

LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim’s® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.

2 Sep 2009

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks.

2 Sep 2009

Research study to identify the appropriate amount of DHA required for promoting optimal heart health

A team of French scientists have found the dose of DHA (docosahexaenoic acid) that is "just right" for preventing cardiovascular disease in healthy men. In a research report appearing in the September 2009 print issue of The FASEB Journal, the scientists show that a 200 mg dose of DHA per day is enough to affect biochemical markers that reliably predict cardiovascular problems, such as those related to aging, atherosclerosis, and diabetes. This study is the first to identify how much DHA is necessary to promote optimal heart health.

1 Sep 2009

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

31 Aug 2009

Health Net urges Americans to have their blood cholesterol measured

Tomorrow, September 1, marks the start of National Cholesterol Education Month. In support of this educational effort, Health Net, Inc., (NYSE: HNT) is encouraging those who haven't yet done so, to have their blood cholesterol measured and, if it's high, to embark on a cholesterol-lowering program.

31 Aug 2009

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

Thickening of neck arteries in healthy middle-aged women with feelings of hopelessness

Healthy middle-aged women with feelings of hopelessness appear to experience thickening of the neck arteries, which can be a precursor to stroke, according to new research out of the University of Minnesota Medical School.

27 Aug 2009

Health Canada issues marketing approval for NeuroVasx's cPAX Aneurysm Treatment System

NeuroVasx, Inc., a medical device company that develops technologies for the treatment of hemorrhagic and ischemic stroke, announced today that it has received approval to market its cPAX Aneurysm Treatment System in Canada from Health Canada's Therapeutic Products Directorate. In addition to Canadian regulatory approval, the cPAX System also received CE Mark in March 2009.

27 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Even as low-carbohydrate/high-protein diets have proven successful at helping individuals rapidly lose weight, little is known about the diets' long-term effects on vascular health.

25 Aug 2009

Studies reveal that obese men are at increased risk for erectile dysfunction

Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Inc.

25 Aug 2009

Thick blood to cause or prevent strokes and heart attacks proved by scientists

"Thick" blood can cause heart attack and stroke, but also prevent them. Scientists at Heidelberg University Hospital have explained the mechanism of this clinical paradox for the first time on an animal model. Mice with a greater tendency to form blood clots have larger plaques in their vessels, but they are more stable.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Micrus Endovascular Corporation and Flexible Stenting Solutions to jointly develop flow diversion technology for neurovascular indications

Micrus Endovascular Corporation and privately held Flexible Stenting Solutions Inc. of Eatontown, N.J., today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications using both Micrus and Flexible Stenting Solutions technology, development capabilities and intellectual property.

24 Aug 2009

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Low levels of vitamin D are known to nearly double the risk of cardiovascular disease in patients with diabetes, and researchers at Washington University School of Medicine in St. Louis now think they know why.

24 Aug 2009

Atherosclerosis News and Research

Further Reading

Second-hand tobacco smoke exposure results in NAFLD

Endothelin research update to be presented at APS' 11th International Conference

Therapeutic principles of monoclonal antibodies

Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth

94-year-old crusader seeks ban on trans fats in the American diet

LifeVantage granted third patent for Protandim

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

Research study to identify the appropriate amount of DHA required for promoting optimal heart health

CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

Health Net urges Americans to have their blood cholesterol measured

DYSlipidemia International Study results presented at the ESC congress

Thickening of neck arteries in healthy middle-aged women with feelings of hopelessness

Health Canada issues marketing approval for NeuroVasx's cPAX Aneurysm Treatment System

Karo Bio collaborates with Wyeth for treating inflammatory diseases

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Studies reveal that obese men are at increased risk for erectile dysfunction

Thick blood to cause or prevent strokes and heart attacks proved by scientists

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Micrus Endovascular Corporation and Flexible Stenting Solutions to jointly develop flow diversion technology for neurovascular indications

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News